文献速递肺外科

复杂肺段切除术治疗高代谢临床IA期非小细胞肺癌

Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer.
PubMed 文献 · Ann Thorac Surg · 2021-05-20

该回顾性多中心研究纳入717例影像学高代谢(最大标准化摄取值≥2.5)的临床IA期非小细胞肺癌患者,比较复杂肺段切除术(n=61)与位置调整肺叶切除术(n=656)的肿瘤学结局。结论认为复杂肺段切除术治疗此类高代谢IA期肺癌不损害肿瘤学结果。

要点

  • 高代谢(SUVmax≥2.5)临床IA期NSCLC行复杂肺段切除术与肺叶切除术的5年肿瘤学结局无显著差异。
  • 倾向性评分匹配后复杂肺段切除术5年癌症特异性生存率89.9%,肺叶切除术83.6%。
  • 多变量分析显示复杂肺段切除术与肺叶切除术复发风险无显著差异(HR 0.84,95%CI 0.25-2.14)。

核心结论

  • 对于影像学高代谢的临床IA期NSCLC,复杂肺段切除术与肺叶切除术的肿瘤学结局无显著差异,复杂肺段切除术不损害肿瘤学结果。

研究设计与样本

  • 回顾性多中心研究,纳入2010至2019年三个机构717例影像学高代谢(SUVmax≥2.5)的临床IA期NSCLC患者,其中复杂肺段切除术61例,位置调整肺叶切除术656例。
  • 采用倾向性评分匹配分析(55对),并用Kaplan-Meier法和Cox比例风险回归评估影响肿瘤学结局的因素。

主要发现

  • 55对倾向性评分匹配后,复杂肺段切除术5年癌症特异性生存率89.9%、无复发生存间期83%,肺叶切除术分别为83.6%和82.5%,差异均无统计学意义。

临床怎么用

  • 对于影像学高代谢(SUVmax≥2.5)的临床IA期NSCLC,复杂肺段切除术可作为不损害肿瘤学结果的手术选择。

局限性

  • 本研究为回顾性研究,复杂肺段切除术组样本量较小(n=61),倾向性评分匹配后仅55对,可能存在选择偏倚和残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to its invasiveness, the indications for "complex segmentectomy" for radiologically hypermetabolic (high maximum standard uptake value) non-small cell lung cancer (NSCLC) remain controversial. This study compared the outcomes after complex segmentectomy and lobectomy in these patients. METHODS: We retrospectively reviewed 717 patients with radiologically hypermetabolic (maximum standardized uptake value ≥2.5), clinical stage IA NSCLC who underwent complex segmentectomy (n = 61) or location-adjusted lobectomy (n = 656) at three institutions from 2010 to 2019. Postoperative outcomes were analyzed for all patients and their propensity score matched pairs. Factors affecting oncologic outcomes were assessed by Kaplan-Meier estimates and Cox proportional hazards regression analyses. RESULTS: The prognosis of patients undergoing complex segmentectomy was not significantly different from that of patients undergoing lobectomy (5-year cancer-specific survival rate, 89.9% vs 91.1%, P = .98; and 5-year recurrence-free interval rate, 83% vs 77.5%, P = .62) in the nonadjusted cohort. In 55 propensity score matched pairs, oncologic outcomes were not significantly different between patients undergoing complex segmentectomy (5-year cancer-specific survival, 89.9%; 5-year recurrence-free interval, 83%) and lobectomy (5-year cancer-specific survival, 83.6%; 5-year recurrence-free interval, 82.5%). Multivariable Cox regression analysis for recurrence-free interval revealed no significant differences between oncologic outcomes associated with complex segmentectomy and lobectomy (hazard ratio, 0.84; 95% confidence interval, 0.25 to 2.14; P = .74). CONCLUSIONS: Oncologic outcomes of complex segmentectomy and lobectomy were not significantly different for patients with radiologically hypermetabolic, clinical stage IA NSCLC patients. Complex segmentectomy can treat high maximum standardized uptake value, clinical stage IA lung cancers without compromising oncologic results.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Handa Y, Tsutani Y, Mimae T, et al. Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer. Ann Thorac Surg. 2021. PMID: 34022215. doi:10.1016/j.athoracsur.2021.04.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。